Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -104.94M | -115.55M | -134.34M | -150.07M | -148.21M |
| Total Depreciation and Amortization | 1.42M | 1.23M | 1.14M | 1.10M | 1.04M |
| Total Amortization of Deferred Charges | 507.00K | 482.00K | 455.00K | 427.00K | 418.00K |
| Total Other Non-Cash Items | 26.61M | 26.98M | 25.80M | 24.39M | 20.31M |
| Change in Net Operating Assets | 10.52M | 3.84M | 6.76M | 261.00K | -6.88M |
| Cash from Operations | -65.89M | -83.03M | -100.18M | -123.89M | -133.31M |
| Capital Expenditure | -1.98M | -1.57M | -1.50M | -1.59M | -1.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -129.93M | -197.63M | -120.28M | -75.94M | 28.42M |
| Cash from Investing | -131.91M | -199.20M | -121.77M | -77.53M | 27.09M |
| Total Debt Issued | 75.00M | 75.00M | 75.00M | 80.00M | 5.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 140.17M | 103.01M | 119.84M | 219.06M | 219.57M |
| Repurchase of Common Stock | -6.69M | -6.69M | -6.69M | -6.69M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.04M | -16.67M | -16.67M | -16.63M | 9.37M |
| Cash from Financing | 182.45M | 154.66M | 171.49M | 275.74M | 233.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.36M | -127.57M | -50.46M | 74.32M | 127.71M |